PMNHIGH SIGNALFINANCIAL10-K

PMN removed going-concern language while experiencing a substantial decline in cash position and significant share count reduction, indicating major corporate restructuring activity.

The removal of going-concern warnings and Nasdaq delisting risks suggests PMN successfully addressed its immediate financial distress, likely through the equity financing that dramatically reduced the share count from 32.7M to 9.0M shares. However, the company's cash position declined substantially to $6.1M, and management still acknowledges continued losses and future financing needs, indicating ongoing financial challenges despite the recent capital raise.

Comparing 2026-03-25 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

PMN's balance sheet reflects significant corporate activity with cash declining substantially from $13.3M to $6.1M and total assets falling by roughly half to $9.2M. The minimal capital expenditures of only $2K suggest the company is operating in cash preservation mode. Despite the cash decline, the dramatic reduction in share count combined with removal of going-concern language indicates PMN likely completed a substantial financing transaction that temporarily stabilized its position while significantly diluting existing shareholders.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-67.2%
$6K$2K

Capex reduced 67.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-54%
$13.3M$6.1M

Cash declined 54% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Assets
Balance Sheet
-51.4%
$18.9M$9.2M

Total assets contracted 51.4% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-51.4%
$18.9M$9.2M

Current assets declined 51.4% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-31
ADDED
The number of outstanding Common Shares of the Registrant as of March 25, 2026 was 8,967,693 .
Risks Related to Our Financial Position and Capital Needs We have incurred losses since inception, we anticipate that we will incur continued losses for the foreseeable future and will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.
There is no active market for our warrants and pre-funded warrants.
The ProMIS platform offers the ability to identify targets (conformational epitopes) unique to the toxic, misfolded form.
Based on current clinical trial patient visit schedules, the Company expects to complete the six-month assessments in the second quarter of 2026, with the blinded interim analysis anticipated in early third quarter 2026.
+7 more — sign up free →
REMOVED
The number of outstanding Common Shares of the Registrant as of March 29, 2025 was 32,689,190 .
Risks Related to Our Financial Position and Capital Needs We have incurred losses since inception, we anticipate that we will incur continued losses for the foreseeable future and there is substantial doubt about our ability to continue as a going concern for the full one-year period following the issuance of the consolidated financial statements.
We will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.
Public Company We are currently not in compliance with Nasdaq s continued listing requirements.
If we are unable to regain compliance with Nasdaq s listing requirements, our Common Shares could be delisted, which could affect the market price of our Common Shares and liquidity and reduce our ability to raise capital.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →